key: cord-0980890-meby3vat
authors: Anjan, Shweta; Natori, Yoichiro; Fernandez Betances, Anmary A.; Agritelley, Matthew S.; Mattiazzi, Adela; Arosemena, Leopoldo; Andrews, David M.; Simkins, Jacques; Guerra, Giselle; Abbo, Lilian M.
title: Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida
date: 2021-10-01
journal: Transplantation
DOI: 10.1097/tp.0000000000003902
sha: c1fc1f1d1a361289e06a94b92389686ff1f6edd9
doc_id: 980890
cord_uid: meby3vat

nan

A dministration of coronavirus disease 2019 (COVID-19) vaccines is critical to ending the pandemic. The available mRNA vaccines are 94%-95% effective in preventing COVID-19 in the general population. Vaccineinduced antibody responses are reported to be lower in solid organ transplant recipients (SOTRs) compared with the general population; 17% after the first dose and 54% after the second dose, with poor response, are generally associated with the use of antimetabolite agents. 1 In the United States, approximately 101 million persons are fully vaccinated with vaccine breakthrough infections reported in 10 262 (breakthrough rate 0.01%) 2 as of April 30, 2021. Data on postvaccine infections in SOTRs are limited.

We reported the largest series of vaccine breakthrough COVID-19 infections in SOTRs in the United States (the study approved by the University of Miami Institutional Review Board). Twenty-six patients were diagnosed with COVID-19 infection by nasopharyngeal polymerase chain reaction, after receiving 1 (n = 3, 12%) or both (n = 23, 89%) doses of BNT162b2 (Pfizer-BioNTech) vaccine. They had no prior COVID-19 infection. The mean age at the time of vaccination was 58 y (32-81); 54% were males and 72% were of Hispanic ethnicity. Eleven patients (42.3%) reported exposure to unvaccinated family members with COVID-19. The median time from transplant to the vaccine (first dose) was 31 mo (range, 0.7-272), with 4 (15.3%) within 6 mo of transplant, and from vaccine to diagnosis was 34 d (range, 4-96). Antibody testing targeting the spike protein was performed via the VITROS test to measure immunoglobulin G and total antibodies ( Table 1 ). All patients were symptomatic. Thirteen patients (50%) required hospital admission and were treated with remdesivir (92.3%, n = 12), high-dose steroids (84.6%, n = 11), and therapeutic plasma exchange (23%, n = 3; only for refractory cases in cytokine storm). Twelve patients (46%) were managed outpatient with early administration of monoclonal antibodies (MABs; casirivimab/imdevimab); all recovered with no progression of the disease. Two (16.6%) were admitted within 28 d of receiving MABs for non-COVID-19 issues. At a median follow-up of 28.5 d (range, 2-75), 5 (19.2%) had severe COVID-19 and 2 (7.6%) patients died. None of them developed rejection or graft loss.

As of April 30, 2021, 2957 SOTRs have been vaccinated at our center, with 26 cases of vaccine breakthrough infection (breakthrough rate 0.87%), which is higher than that reported in the general population. Our findings confirmed that severe COVID-19 and mortality can occur from vaccine breakthrough infections in SOTRs. 3, 4 Data show transplant patients developed cellular and humoral responses despite immunosuppression, suggesting that vaccinated SOTRs may benefit from the vaccine even in the absence of antibody response. 5 In conclusion, SOTRs remain at risk of severe COVID-19 even after the vaccination. Vaccinating SOTRs and ring vaccination of close contacts may provide better protection to immunocompromised patients. Transplant centers should continue to reinforce social distancing, mask use, and handwashing in fully vaccinated SOTR, even though mask mandates are relaxed nationally. Multicenter studies assessing cellular and humoral immunogenicity data, role of booster doses, use of MABs as prophylaxis in adjunct to vaccines, and genomic sequencing to identify variants causing vaccine breakthrough infections are needed. 

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

COVID-19 vaccine breakthrough infections reported to CDC-United States

Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients

Development of COVID-19 infection in transplant recipients after SARS-CoV-2 vaccination

The magnitude and functionality of SARS-CoV-2 reactive cellular and humoral immunity in transplant population is similar to the general population despite immunosuppression. Transplantation. [Epub ahead of print